Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011
With reference to the captioned subject, please find enclosed the following two disclosures under regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011: 1. Sale of 533 Equity Shares of Rs. 10/- each by Ramanbhai B. Patel (HUF), Promoter Group, in open market and 2. Purchase of 533 Equity Shares of Rs. 10/- each by Pankaj Ramanbhai Patel (HUF), Promoter Group, from open market. Zydus gets USFDA final nod to mkt drugs for stomach ailments such as ulcer
The drug is also used to for preventing stomach bleeding in very ill patents Updates
Change in authority for making Disclosures under Regulation 30 [5] of SEBI (Listing Obligation and Disclosure Requirements), 2015
Zydus Wellness Q3 profit rises 44% to Rs36 crore
Zydus Wellness' consolidated net profit jumps 43.83% to Rs36.16 crore for the December quarter of the current fiscal Appointment of Chief Financial Officer (CFO)
Pursuant to Regulation 30 of the Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements], 2015, we inform that Audit Committee/Board of Directors have in their meetings both held on February 7, 2018 appointed Mr. Umesh Parikh as a Chief Financial Officer of the Company with effect from today i.e. February 7, 2018.... Un-Audited Financial Results For The Quarter/Nine Months Ended December 31, 2017
Please find attached herewith the un-audited financial results for the quarter / nine months ended on December 31, 2017, reviewed by the Audit Committee and taken on record by the Board of Directors today i.e. February 7, 2018 pursuant to Regulation No. 33[2][a] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015 along with Limited Review Reports [Standalone and Consolidated] and Press Release. Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a teleconference call at 5.00 p.m. on Wednesday, February 7, 2018 for Q3 FY 18 post results Q&A; session. Skin care or functional food? Zydus Wellness eyes acquisitions in FY19
With Rs 4,897 mn cash in balance sheet and a 94 per cent category share in artificial sweeteners, the company is eyeing the inorganic route to propel growth Shareholding for the Period Ended December 31, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Notice For The Meeting Of The Board Of Directors / Closure Of Trading Window
We hereby inform that a meeting of the Board of Directors of the Company will be held on Wednesday, February 7, 2018 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015 as amended from time to time,...